Can-Fite submits pediatric plan to FDA for Piclidenoson in psoriasis treatment

Can-Fite submits pediatric plan to FDA for Piclidenoson in psoriasis treatment

Biotech leader Can-Fite BioPharma, known for its advances in oncology, inflammatory, and liver diseases, has taken a significant step forward with its announcement today of the submission of a pediatric study plan to the U.S. Food and Drug Administration (FDA). This ambitious move is for the treatment of adolescents with psoriasis using their proprietary drug […]